A Phase 3 interventional study of Sofetabart Mipitecan and Paclitaxel in Ovarian Neoplasms, Fallopian Tube Neoplasms and Peritoneal Neoplasms, sponsored by Eli Lilly and Company. Recruiting at 264 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.
Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 2nd largest by planned enrollment, is one of 9 that started in 2025, is one of 18 in phase 3, reaches primary completion later than 23 of the 31 other live ones, and was the 99th registered.
3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
CSPC Megalith Biopharmaceutical Co.,Ltd. · Sites in China
Ages 18+
Jiangsu Cancer Institute & Hospital · Sites in China
Ages 18–75
Medical University of South Carolina · Sites in United States
Ages 18+
Nanjing Leads Biolabs Co.,Ltd · Sites in China
Ages 18+
AbbVie · Sites in United States, Australia, Belgium and 5 more countries
Ages 18+ · Women only
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 73 · Phase 3 20 · Phase 4 2
First in 2003; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,630 is above the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 52 across the 106 interventional studies. Of the 60 that completed or were terminated, 37 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 106 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
29 studies in Ovarian Neoplasms by Eli Lilly and Company: 6 open now, 9 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 29 studies in Ovarian Neoplasms by Eli Lilly and Company, this one has the largest planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 27th registered.
Eli Lilly and Company’s Ovarian Neoplasms studies by the year they started, since 1998.
7 of the studies testing bevacizumab in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT05636111M.D. Anderson Cancer CenterPhase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | 2026-12-31 |
| NCT02884648M.D. Anderson Cancer CenterBevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | 2027-02-02 |
| NCT07453394Qilu Pharmaceutical Co., Ltd.QLS5132 Combination Therapy in Advanced Solid Tumors | 2027-04 |
| NCT06799065Accent TherapeuticsFirst-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies testing bevacizumab in Ovarian Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 29 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with platinum-resistant cancer, meaning their disease progressed during or within six months of platinum-based chemotherapy. Parts B and C enroll participants with platinum-sensitive cancer, whose disease responded and remained controlled for at least six months after completing platinum treatment. The researchers want to find out if Sofe-M works better than the standard treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A, B, and C:
Part A:
Part B and C:
Part B:
- Have previously received a PARPi, per local product label, with progression on, or within 6 months of completion of PARPi treatment.
Part C:
- Have not previously received a PARPi treatment.
Exclusion Criteria:
Parts A, B and C:
- Have received prior antibody-drug conjugate (ADC) with a topoisomerase inhibitor payload.
Part A:
Part B and C:
- Have proteinuria
Part C:
- Have a known pathogenic BRCA1/2 gene alteration (somatic or germline).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered intravenously (IV).
Drug: Sofetabart Mipitecan
Investigator's Choice of Chemotherapy or MIRV given IV.
Drug: Paclitaxel · Drug: Topotecan · Drug: Gemcitabine · Drug: Pegylated liposomal doxorubicin (PLD) · Drug: MIRV
Administered IV.
Drug: Sofetabart Mipitecan · Drug: Bevacizumab
Investigator's choice of platinum doublet chemotherapy IV followed by bevacizumab IV.
Drug: Paclitaxel · Drug: Gemcitabine · Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Bevacizumab · Drug: Carboplatin
Administered IV
Drug: Sofetabart Mipitecan · Drug: Bevacizumab
Investigator's choice of platinum doublet chemotherapy IV followed by bevacizumab IV.
Drug: Paclitaxel · Drug: Gemcitabine · Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Bevacizumab · Drug: Carboplatin
Administered IV
Also known as: LY4170156, Sofe-M
Administered IV
Administered IV
Administered IV
Administered IV
Administered IV
Administered IV
Administered IV
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator
Time frame: Randomization to radiographic progression or death from any cause (up to 70 months)
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded, Independent, Central Review (BICR)
Time frame: Randomization to radiographic progression or death from any cause (up to 70 months)
Overall Survival (OS)
Time frame: Randomization to date of death from any cause (up to 70 months)
PFS
PFS by blinded independent central review (BICR)
Time frame: Randomization to radiographic progression or death from any cause (up to 70 months)
Overall Response Rate (ORR): Proportion of Participants who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
ORR per RECIST v1.1
Time frame: Randomization to disease progression or death (up to 70 months)
Duration of Response (DOR)
DOR per RECIST v1.1
Time frame: Date of first documented CR or PR to date of radiographic progression or death from any cause (up to 70 months)
Disease Control Rate (DCR): Proportion of Participants who Achieve a BOR of CR, PR, or Stable Disease (SD)
DCR per RECIST v1.1
Time frame: Randomization to disease progression or death from any cause (up to 70 months)
PFS2
Time frame: Randomization to disease progression on next line of treatment or death from any cause (up to 70 months)
Time to Initiation of First Subsequent Systemic Anticancer Therapy or Death (TNTD)
Time frame: Randomization to initiation of subsequent systemic anticancer or death from any cause (up to 70 months)
Proportion of Participants with Response of Cancer Antigen-125 (CA-125) per Gynecologic Cancer Intergroup Criteria (GCIG)
Per GCIG
Time frame: Randomization to 30 days post treatment discontinuation
Percentage of Assessments with High Side-effect Bother, as measured by Functional Assessment of Cancer Therapy - General Item 5 (FACT GP5)
FACT-GP5 is a single-item, patient-reported instrument for assessing overall treatment side-effect burden. High side effect bother is defined as a score of 3 or 4 on a 5-point Likert scale. Higher scores represent higher symptom burden.
Time frame: Randomization to 30 days post treatment discontinuation
Change from Baseline in Abdominal/GI Symptoms, as measured by the European Organization for Research and Treatment of Cancer Ovarian Cancer Module (EORTC OV28)
The EORTC OV28 consists of 28 items covering 3 functional scales and 5 symptom scales. The Abdominal/GI symptom scale ranges from 0 to 100. Higher scores indicate worse symptoms.
Time frame: Randomization to 30 days post treatment discontinuation
Change from Baseline in Overall Health-related Quality of Life (HRQoL), as measured by the EORTC QLQ-C30 Global Health Status/Quality of Life Subscale
The EORTC QLQ-C30 is a 30-question patient-reported instrument used to assess multidimensional HRQoL in cancer patients. Overall HRQoL is measured by the EORTC QLQ-30 Global Health Status/Quality of Life Subscale (two items). Response options range from 0 - 100. Higher score represents better overall HRQoL.
Time frame: Randomization to 30 days post treatment discontinuation
Pharmacokinetics (PK): Minimum Blood Plasma Concentration (Cmin) of LY4170156
Time frame: Randomization through end of treatment (up to 70 months)]
PFS
PFS by investigator assessment per RECIST v1.1
Time frame: Randomization to radiographic progression or death from any cause (up to 70 months)
Showing the first 100 of 264 sites across 27 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Oct 2025 (actual). Primary completion is estimated for Nov 2028, 37 months after the start.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 37 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab